{'52WeekChange': -0.292876,
 'SandP52WeekChange': 0.0644362,
 'address1': '310 Utah Avenue',
 'address2': 'Suite 150',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.25,
 'askSize': 1000,
 'averageDailyVolume10Day': 121125,
 'averageVolume': 164679,
 'averageVolume10days': 121125,
 'beta': None,
 'beta3Year': None,
 'bid': 7.9,
 'bidSize': 900,
 'bookValue': 3.534,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8.43,
 'dayLow': 7.92,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.706,
 'enterpriseToRevenue': 2.315,
 'enterpriseValue': 95519232,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 872 8924',
 'fiftyDayAverage': 8.771714,
 'fiftyTwoWeekHigh': 12.75,
 'fiftyTwoWeekLow': 6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14838447,
 'forwardEps': -2.7,
 'forwardPE': -2.9777777,
 'fromCurrency': None,
 'fullTimeEmployees': 177,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.21157,
 'heldPercentInstitutions': 0.69522005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/sutrobio.com',
 'longBusinessSummary': 'Sutro Biopharma, Inc. operates as clinical stage drug '
                        'discovery, development, and manufacturing company. It '
                        'focuses on creating protein therapeutics for cancer '
                        'and autoimmune disorders through integrated cell-free '
                        'protein synthesis and site-specific conjugation '
                        "platform, XpressCF. The company's product candidates "
                        'include STRO-001, an antibody-drug conjugate (ADC) '
                        'directed against the cancer target CD74 for patients '
                        'with multiple myeloma and non-Hodgkin lymphoma; and '
                        'STRO-002, an ADC directed against folate '
                        'receptor-alpha for patients with ovarian and '
                        'endometrial cancers. It has collaboration and license '
                        'agreement with Celgene Corporation to discover and '
                        'develop bispecific antibodies and/or ADCs focused '
                        'primarily on the field of immuno-oncology. The '
                        'company was formerly known as Fundamental Applied '
                        'Biology, Inc. Sutro Biopharma, Inc. was incorporated '
                        'in 2003 and is headquartered in South San Francisco, '
                        'California.',
 'longName': 'Sutro Biopharma, Inc.',
 'market': 'us_market',
 'marketCap': 288461536,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_38768157',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -61089000,
 'nextFiscalYearEnd': 1640908800,
 'open': 8.15,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.14,
 'phone': '650 392 8412',
 'previousClose': 8.22,
 'priceHint': 2,
 'priceToBook': 2.2750425,
 'priceToSalesTrailing12Months': 6.9914813,
 'profitMargins': -1.4806199,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8.43,
 'regularMarketDayLow': 7.92,
 'regularMarketOpen': 8.15,
 'regularMarketPreviousClose': 8.22,
 'regularMarketPrice': 8.15,
 'regularMarketVolume': 57895,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 35878300,
 'sharesPercentSharesOut': 0.0198,
 'sharesShort': 711584,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 64069,
 'shortName': 'Sutro Biopharma, Inc.',
 'shortPercentOfFloat': 0.023,
 'shortRatio': 3.09,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'STRO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.651,
 'twoHundredDayAverage': 9.817266,
 'volume': 57895,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.sutrobio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}